DiscoveryProbe™ FDA-approved Drug Library: A Gold Standard in High-Throughput Bioactive Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) offers a systematically curated set of 2,320 bioactive compounds approved by the FDA, EMA, HMA, CFDA, and PMDA, or listed in authoritative pharmacopeias (ApexBio, 2024). All compounds are supplied as 10 mM DMSO solutions in standardized plate or tube formats, ensuring reproducibility (SB-334867.com, 2024). The library accelerates drug repositioning, target identification, and mechanistic studies in oncology, neurodegeneration, and rare disease research (Park et al., 2025). Experimental evidence demonstrates the use of this library for identifying novel therapeutic roles for approved drugs, such as the repositioning of sulfasalazine for sarcopenia (Park et al., 2025). The resource is widely adopted for high-throughput screening (HTS) and high-content screening (HCS), supporting robust, scalable pharmacological workflows (BKM120.net, 2024).

Biological Rationale

Clinically approved drugs have well-characterized pharmacokinetic and pharmacodynamic profiles, making them ideal candidates for drug repositioning and mechanistic studies (Park et al., 2025). The DiscoveryProbe™ FDA-approved Drug Library leverages this advantage by aggregating drugs with diverse mechanisms, including receptor agonists and antagonists, enzyme inhibitors, ion channel modulators, and signaling pathway regulators. This enables systematic investigation of biological pathways implicated in disease models—such as the role of NF-κB and YY1 in muscle wasting—or the identification of compounds with previously unrecognized efficacy in new indications. Approved drugs like doxorubicin, metformin, and atorvastatin serve as reference points for pharmacological validation. By focusing on compounds with clinical histories, researchers can accelerate translational research while reducing the risks associated with de novo chemical entities.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library comprises compounds acting across a broad spectrum of molecular targets:

• Receptor Agonists/Antagonists: Molecules modulating GPCRs, nuclear receptors, and cytokine receptors facilitate pathway dissection in HTS assays (GENS-Bio.com, 2024).
• Enzyme Inhibitors: Compounds targeting kinases, phosphatases, and proteases, enabling screens for signal pathway regulation or metabolic intervention.
• Ion Channel Modulators: Agents affecting calcium, sodium, potassium, and chloride channels are critical for neurodegeneration and cardiac research.
• Signal Pathway Regulators: Compounds with documented effects on canonical pathways such as NF-κB, PI3K/AKT, MAPK, and Wnt/β-catenin.

All compounds are provided as 10 mM solutions in DMSO, with validated stability for 12 months at -20°C and up to 24 months at -80°C. The uniform concentration and solvent facilitate direct transfer to screening platforms, minimizing variability.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library enabled the identification of sulfasalazine as an inhibitor of PHF20-induced YY1 promoter activity (IC50 = 24 μM) in C2C12 myoblasts, supporting its repositioning for sarcopenia (Park et al., 2025, DOI).
• In mouse models, sulfasalazine from the library enhanced muscle strength and function, and prevented muscle mass loss, demonstrating in vivo efficacy (Park et al., 2025, DOI).
• Clinical records of IBD patients treated with sulfasalazine showed significantly higher total psoas index (TPI), indicating muscle preservation (Park et al., 2025, DOI).
• The library's standardized format supports high-content imaging and automated liquid handling, with error rates below 2% in multi-lab benchmarking (BKM120.net, 2024, link).
• Mechanistically diverse compounds enable pathway-specific screens, as exemplified by successful identification of functionally selective GPCR ligands (GENS-Bio.com, 2024, link).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for:

• High-throughput screening (HTS) and high-content screening (HCS) in oncology, neurodegenerative, metabolic, and rare disease research.
• Drug repositioning, enabling rapid identification of new indications for known molecules.
• Mechanistic studies, including pathway mapping and target deconvolution.
• Pharmacological validation using clinically relevant compounds with established human safety data.

Compared to the thought-leadership article "From Mechanism to Medicine: Reimagining Translational Discovery", which focuses on the paradigm shift in translational research, this dossier provides detailed, evidence-backed benchmarks and operational boundaries for deploying the DiscoveryProbe™ library in real-world laboratory settings.

For a workflow-centric perspective, see "Next-Generation High-Throughput Screening: Mechanistic Integration", which describes how comprehensive libraries such as DiscoveryProbe™ are revolutionizing screening protocols. This article extends that discussion with precise stability parameters, compound diversity statistics, and evidence from recent peer-reviewed studies.

For design and troubleshooting tips, "DiscoveryProbe FDA-approved Drug Library: Accelerating Drug Repositioning" provides practical recommendations, while this dossier clarifies the library’s mechanistic breadth and evidence base.

Common Pitfalls or Misconceptions

• Not a discovery library for uncharacterized scaffolds: All compounds are clinically approved or pharmacopeia-listed; novel chemical matter is not included.
• Not suitable for structure-activity relationship (SAR) campaigns: The library contains single representatives of each drug, not analog series.
• May not capture all regional approvals: Compounds are selected based on major regulatory agencies; region-specific drugs may be absent.
• Not a substitute for in vivo toxicology: Prior clinical approval does not guarantee safety in new models or combinations.
• Limited utility for ultra-high-throughput (uHTS) beyond 2,320 compounds: The library is not intended for ultra-large screening projects.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is supplied as pre-dissolved 10 mM solutions in DMSO, compatible with 96-well microplates, deep-well plates, and 2D barcoded screw-top tubes. Solutions are stable for 12 months at -20°C and up to 24 months at -80°C. Shipping is on blue ice for evaluation samples, with room temperature or blue ice options for larger formats. The standardized format reduces pipetting variability and supports automation. For each screen, recommended dilution protocols and plate layouts are provided by the supplier (DiscoveryProbe™ FDA-approved Drug Library). The library is designed for seamless integration with automated liquid handlers and imaging systems, minimizing sample loss and cross-contamination.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library stands as a benchmark resource for high-throughput and high-content screening. Its composition of 2,320 well-characterized, clinically approved compounds enables rapid, reproducible pharmacological profiling. Peer-reviewed studies, such as the repositioning of sulfasalazine for sarcopenia, illustrate its translational impact (Park et al., 2025). The library’s operational reliability, mechanism diversity, and compatibility with automation position it as a core asset for accelerating drug discovery, target validation, and mechanistic research across biomedical fields. As new therapeutic challenges emerge, the machine-readable, evidence-anchored nature of this FDA-approved bioactive compound library ensures its continued relevance in both academic and industrial settings.